Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.8K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.8K
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

324
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
324
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

347
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
347
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

582
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
582
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

340
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
340
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

317
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
317

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardiac valve mass revealed by venous and arterial embolism: case report and review of the literature.

European heart journal. Case reports·2026
Same author

Spontaneous coronary artery dissection cohort study: A nationwide Tunisian series.

La Tunisie medicale·2026
Same author

Bridging the gap: adapting heart failure guidelines for resource-limited settings: A European Journal of Heart Failure expert consensus document.

European journal of heart failure·2026
Same author

Hepatic adverse effects of valproic acid: Management strategies.

Indian journal of pharmacology·2026
Same author

First report of Fusarium solani species complex infection on mandarin and maltese in Tunisia and semi-quantitative analysis of mycotoxins production in vitro.

BMC microbiology·2026
Same author

[Lettre to the Editor: Acute anterior uveitis following zoledronate infusion].

La Revue de medecine interne·2026

Related Experiment Video

Updated: Mar 30, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

[Statins Use in Elderly Patients].

Rania Hammami1, Jihen Jdidi2, Faten Triki1

  • 1Service de Cardiologie de Sfax, CHU Hedi Chaker, Sfax, Tunisie.

Therapie
|November 3, 2015
PubMed
Summary
This summary is machine-generated.

Statins effectively reduce cardiovascular risk in younger patients. However, their benefits for cardiovascular mortality in the very elderly, especially in primary prevention, require further investigation, necessitating individualized treatment plans.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.3K

Related Experiment Videos

Last Updated: Mar 30, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.3K

Area of Science:

  • Gerontology
  • Cardiology
  • Pharmacology

Background:

  • Elderly individuals face a higher risk of cardiovascular disease (CVD).
  • Cardiovascular risk-reducing treatments, like statins, are often underprescribed in this demographic.
  • Established benefits of statins exist for secondary prevention in patients under 80 years.

Purpose of the Study:

  • To evaluate the impact of statins on cardiovascular morbidity and mortality in the very elderly population.
  • To assess the efficacy of statins in primary and secondary cardiovascular prevention among geriatric patients.
  • To determine the safety profile and individualized prescribing considerations for statins in the elderly.

Main Methods:

  • Review of existing randomized trials and clinical data on statin use in elderly patients.
  • Analysis of statin effects on myocardial infarction and stroke risk in primary prevention.
  • Examination of data regarding cardiovascular mortality benefits and adverse effects in older adults.

Main Results:

  • Statins reduce myocardial infarction and stroke risk in primary prevention, but cardiovascular mortality benefits remain uncertain in the elderly.
  • No randomized trials specifically address statin impact on morbidity and mortality in very elderly patients for primary or secondary prevention.
  • Adverse effects of statins in the elderly appear statistically similar to younger populations.

Conclusions:

  • Statin prescription in very elderly patients requires individualized assessment, considering life expectancy, quality of life, comorbidities, and potential drug interactions.
  • Further research, including randomized trials, is needed to clarify the role of statins in primary and secondary cardiovascular prevention for the very elderly.
  • While generally safe, careful consideration of individual patient factors is paramount for optimizing statin therapy in geriatric populations.